Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 4%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIOGet Free Report) was up 4% during mid-day trading on Friday . The stock traded as high as $44.63 and last traded at $44.13. Approximately 217,078 shares were traded during mid-day trading, a decline of 73% from the average daily volume of 818,024 shares. The stock had previously closed at $42.45.

Analysts Set New Price Targets

A number of brokerages have recently commented on AGIO. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. The Goldman Sachs Group raised their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, June 4th. Royal Bank of Canada upped their target price on Agios Pharmaceuticals from $44.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday. Finally, StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 29th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $50.67.

View Our Latest Stock Analysis on Agios Pharmaceuticals

Agios Pharmaceuticals Trading Up 4.7 %

The business’s fifty day simple moving average is $36.46 and its 200 day simple moving average is $29.69.

Agios Pharmaceuticals (NASDAQ:AGIOGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) EPS for the quarter, beating the consensus estimate of ($1.65) by $0.20. The business had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative net margin of 1,199.26% and a negative return on equity of 41.41%. Agios Pharmaceuticals’s revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.47) earnings per share. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -2.68 earnings per share for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the transaction, the director now owns 137,396 shares in the company, valued at $3,785,259.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several large investors have recently modified their holdings of AGIO. Farallon Capital Management LLC grew its position in shares of Agios Pharmaceuticals by 34.1% in the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the period. Assenagon Asset Management S.A. raised its position in Agios Pharmaceuticals by 800.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 454,801 shares of the biopharmaceutical company’s stock valued at $13,298,000 after buying an additional 404,297 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Agios Pharmaceuticals by 23.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after acquiring an additional 388,381 shares in the last quarter. Norges Bank bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at approximately $6,826,000. Finally, Frazier Life Sciences Management L.P. grew its stake in shares of Agios Pharmaceuticals by 79.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 523,166 shares of the biopharmaceutical company’s stock worth $11,651,000 after acquiring an additional 231,164 shares in the last quarter.

About Agios Pharmaceuticals

(Get Free Report)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

Read More

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.